Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071202 | 0.83 | HTR2A (0.41) | HTR2AOPRM1MMP2MMP9CHRNB2 | |
| SCHEMBL19482451 | 0.81 | HTR2C (0.34) | HTR2AMMP2MMP9SLC6A2SLC6A3 | |
| SCHEMBL19458987 | 0.81 | HTR2C (0.34) | HTR2AMMP2MMP9SLC6A2SLC6A3 | |
| SCHEMBL11880368 | 0.75 | HTR2A (0.50) | HTR2AOPRM1KDM1AMAOASLC6A2 | |
| SCHEMBL21312268 | 0.73 | OPRM1 (0.42) | HTR2AOPRM1KDM1AMAOAOPRK1 | |
| SCHEMBL15995119 | 0.73 | OPRM1 (0.42) | HTR2AOPRM1KDM1AMAOAOPRK1 | |
| SCHEMBL15995122 | 0.73 | OPRM1 (0.42) | HTR2AOPRM1KDM1AMAOAOPRK1 | |
| SCHEMBL13233728 | 0.72 | HTR2A (0.52) | HTR2AOPRM1 | |
| SCHEMBL10708233 | 0.72 | OPRM1 (0.41) | HTR2AOPRM1SLC6A2SLC6A3OPRK1 | |
| SCHEMBL8594823 | 0.72 | OPRM1 (0.43) | HTR2AOPRM1KDM1AMAOAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103298809-B | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | 杨森制药公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2661435-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8993591-B2 | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2661435-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| CN-103298809-A | 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | JANSSEN PHARMACEUTICALS INC | 2013-09-11 | — | — | CN | disclosed |
| WO-2012062759-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062759-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155393-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | HTR2A 53/4885OPRM1 242/4885KDM1A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.